Carcinogenesis Advance Access originally published online on June 1, 2005
Carcinogenesis 2005 26(11):1890-1895; doi:10.1093/carcin/bgi146
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.26 no.11 © Oxford University Press 2005; all rights reserved.
Biological properties of a human compact anti-ErbB2 antibody
Department of Structural and Functional Biology, University of Naples ‘Federico II’, Via Mezzocannone 16, 80134 Naples, Italy and 1 Department of Organic Chemistry and Biochemistry, University of Naples, ‘Federico II’, Via Cinthia, 80126 Naples, Italy
* To whom correspondence should be addressed. Tel: +39 081 2534731; Fax: +39 081 5521217; Email: dalessio{at}unina.it
ErbB2 is a prognostic factor and target of therapy for many carcinomas. In contrast with the other ErbB receptors, ErbB2 lacks a soluble direct ligand, but it is the preferred co-receptor for the ErbB family members, forming heterodimers with more potent and prolonged signalling activity than that of homodimers. We recently produced a new anti-ErbB2 antibody, Erb-hcAb, by fusion of Erbicin, a human, anti-ErbB2 scFv, selectively cytotoxic to ErbB2-positive cells, and a human Fc domain. This fully human antitumour antibody represents a compact version of an IgG1, with the cytotoxicity of the scFv moiety on target cells, combined with the ability of the Fc moiety to induce both antibody- and complement-dependent cytotoxicity. Here, we describe the main properties of Erb-hcAb, using as a reference Herceptin, an anti-ErbB2 humanized monoclonal currently employed in clinical immunotherapy. We found that both bivalent Erb-hcAb and Herceptin increase receptor phosphorylation and downregulation, whereas monovalent Erbicin does not. These results correlate with the finding that Erb-hcAb is capable of inducing apoptosis and inhibiting cell cycle progression in ErbB2-positive cells. Its powerful in vitro antitumour action matched that observed in vivo in experiments with human ErbB2-positive tumour xenografts established in athymic mice. Finally, Erb-hcAb displays a glycosylation profile virtually superimposable to that of a human IgG. These findings suggest that Erb-hcAb is a very promising new agent for the immunotherapy of carcinomas that overexpress the ErbB2 receptor.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Riccio, G. Esposito, E. Leoncini, R. Contu, G. Condorelli, M. Chiariello, P. Laccetti, S. Hrelia, G. D'Alessio, and C. De Lorenzo Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents FASEB J, September 1, 2009; 23(9): 3171 - 3178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kubetzko, E. Balic, R. Waibel, U. Zangemeister-Wittke, and A. Pluckthun PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5: EFFECTS ON TUMOR TARGETING J. Biol. Chem., November 17, 2006; 281(46): 35186 - 35201. [Abstract] [Full Text] [PDF]
|
|